JP2004217596A - Eye drop agent composition - Google Patents
Eye drop agent composition Download PDFInfo
- Publication number
- JP2004217596A JP2004217596A JP2003009202A JP2003009202A JP2004217596A JP 2004217596 A JP2004217596 A JP 2004217596A JP 2003009202 A JP2003009202 A JP 2003009202A JP 2003009202 A JP2003009202 A JP 2003009202A JP 2004217596 A JP2004217596 A JP 2004217596A
- Authority
- JP
- Japan
- Prior art keywords
- eye
- mass
- agent composition
- phenylephrine
- dry eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 239000003889 eye drop Substances 0.000 title abstract description 6
- 239000003795 chemical substances by application Substances 0.000 title abstract description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 15
- 206010013774 Dry eye Diseases 0.000 claims abstract description 15
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims abstract description 14
- 229960001802 phenylephrine Drugs 0.000 claims abstract description 9
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims abstract description 9
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 claims description 15
- 239000011714 flavin adenine dinucleotide Substances 0.000 claims description 15
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical class OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 8
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 claims description 8
- 230000028327 secretion Effects 0.000 abstract description 11
- 239000000243 solution Substances 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 239000012530 fluid Substances 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 9
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 6
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000003464 asthenopia Diseases 0.000 description 3
- 208000010217 blepharitis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 241001420836 Ophthalmitis Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 208000010403 panophthalmitis Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- XLRHXNIVIZZOON-WFUPGROFSA-L Flavin adenine dinucleotide disodium Chemical compound [Na+].[Na+].C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 XLRHXNIVIZZOON-WFUPGROFSA-L 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Abstract
Description
【０００１】
【発明の属する技術分野】
本発明は、涙液分泌減少に伴うドライアイ、目の疲れ、かすみ、かゆみ、さらには結膜充血、眼瞼炎、コンタクトレンズ着用時の不快感の予防または改善するための点眼用組成物に関する。
【０００２】
【従来の技術】
現代社会において、目を酷使する場面が急増している。その疾患要因の一つにドライアイ（乾燥眼）がある。ドライアイとは一般に、涙液の分泌量の低下や涙液の質的変化により、眼球表面の角膜や結膜が障害をうけた状態のことである。正常な眼の表面では、涙はまばたきにより、薄い膜となり、乾燥、ほこり、細菌から眼を守っている。しかし、ドライアイになると、眼の表面を十分に保護できなくなり、角膜や結膜に障害が生じることになる。ドライアイは単に眼が乾くだけでなく、眼の表面を傷つけることからも、様々な眼病に発展する前に早期対策が必要である。
【０００３】
涙液は油層、水層、ムチン層の３層より構成されており、これまでに用いられているドライアイの一般的な治療法としては、水層の補給を目的とした人工涙液の点眼やムチン層の補給を目的として保水効果のあるコンドロイチン硫酸ナトリウム、ヒアルロン酸ナトリウムなどの点眼が行われている。しかし、これらはいずれも本来の涙液分泌を促進させるものではない。
【０００４】
従来、フェニレフリンは血管収縮作用に基づく充血除去を目的に点眼剤に広く配合されてきた。また、フラビンアデニンジヌクレオチド（ＦＡＤと省略できる）については、既にドライアイの治療に有効であることが知られている（特許文献１）。
【特許文献１】
特開平１１−２６３７２９号公報
【０００５】
【発明が解決しようとする課題】
本発明は、積極的に涙液の分泌を促進させることにより、より効果が優れ、かつ安全にドライアイに伴う諸症状を改善する点眼剤組成物を提供することを目的とする。
【０００６】
【課題を解決するための手段】
本発明者らは上記課題を解決するために鋭意検討を行った結果、フェニレフリンとフラビンアデニンジヌクレオチドを組み合わせることにより、相乗的に涙液分泌促進作用を増強することを見出し、本発明を完成した。
【０００７】
すなわち、本発明は、（１）フェニレフリンおよびビタミンＢ２類を配合したことを特徴とする点眼用組成物、（２）ビタミンＢ２類がフラビンアデニンジヌクレオチドであることを特徴とする（１）記載の点眼用組成物、（３）ドライアイの予防または改善用である（１）又は（２）記載の点眼用組成物である。
【０００８】
【発明の実施の形態】
本発明は、涙液分泌減少に伴うドライアイ、目の疲れ、かすみ、かゆみ、さらには結膜充血、眼瞼炎、眼炎、コンタクトレンズ着用時の不快感の予防または改善するために有効である。
【０００９】
本発明に用いるビタミンＢ２類には、フラビンアデニンジヌクレオチドおよびその塩類、リン酸リボフラビンおよびその塩類、酢酸リボフラビン、酪酸リボフラビンなどが挙げられる。これらのうち、好ましくはフラビンアデニンジヌクレオチドが挙げられ、最も好ましくはフラビンアデニンジヌクレオチド・二ナトリウムが挙げられる。フラビンアデニンジヌクレオチドを用いる場合には、液剤全体の０．００５質量％〜５．０質量％の割合で配合することができ、好ましくは０．０１質量％〜１．０質量％であり、さらに好ましくは０．０２質量％〜０．０５質量％である。
【００１０】
本発明に用いるフェニレフリンは、０．０００１質量％〜１０．０質量％の割合で配合することができ、好ましくは０．００５質量％〜１．０質量％であり、さらに好ましくは０．０１質量％〜０．１質量％である。またフェニレフリンとしては配合形態は限定されないが、塩酸フェニレフリンが特に好ましい。
【００１１】
本発明は、発明の効果を損なわない質的および量的範囲で、必要に応じて他の薬効成分を配合することができる。
【００１２】
【発明の効果】
本発明により、涙液分泌減少に伴うドライアイ、目の疲れ、かすみ、かゆみ、さらには結膜充血、眼瞼炎、眼炎、コンタクトレンズ着用時の不快感の予防または改善するための点眼用組成物の提供が可能になった。
【００１３】
【実施例】
以下に試験例および実施例をあげ、本発明を具体的に説明する。
試験例１、比較例１〜２、対照例１
体重約２．５Ｋｇの雄性日本白色ウサギを１群５匹とした。ウサギの眼に０．４質量％塩酸オキシブプロカイン５０μｌを３分間隔で２回点眼し、その３分後に片眼に被験点眼サンプルを、他眼には生理食塩水を、それぞれ５０μｌ点眼した。被験点眼サンプルは、それぞれ、生理食塩水に溶解し、以下の濃度に調整した。点眼後、５分、１０分、１５分、３０分後に、シルマー試験紙（５ｍｍ×３５ｍｍの短冊状の濾紙）を下瞼に１分間挿入することにより涙液を採取した。涙液分泌量は、シルマー試験紙のぬれている長さを、ノギスを用いて測定し、それぞれその長さの合計値から涙液の量を測定した。
比較例１：０．１質量％塩酸フェニレフリンを含有する溶液
比較例２：０．０５質量％ＦＡＤ溶液を含有する溶液
試験例１：０．１質量％塩酸フェニレフリン溶液および０．０５質量％ＦＡＤ溶液を含有する溶液
結果
結果を表１に示した。
【００１４】
【表１】
表１に示したごとく、比較例１の０．１質量％塩酸フェニレフリン溶液および比較例２の０．０５質量％ＦＡＤ溶液は生理食塩水と比較して、涙液分泌量に変化は見られなかったが、試験例１の０．１質量％塩酸フェニレフリン溶液および０．０５質量％ＦＡＤ溶液には涙液分泌量の有意な増加がみられた。以上の結果から、フェニレフリンとＦＡＤを配合した点眼用組成物は、ＦＡＤ単独あるいはフェニレフリン単独と比較して涙液分泌促進作用が増強されることが明らかになった。
実施例１
フェニレフリン塩酸塩０．１ｇ、フラビンアデニンジヌクレオチド二ナトリウム０．０５ｇを滅菌精製水９０ｍｌに溶解し、ホウ砂でｐＨを７．４に調製した後、滅菌精製水を加えて全量を１００ｍｌとし、点眼剤を調製した。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to an ophthalmic composition for preventing or improving dry eye, eye fatigue, blurring, itching, conjunctival congestion, blepharitis, and discomfort when wearing a contact lens due to a decrease in tear secretion.
[0002]
[Prior art]
In modern society, scenes of overworking eyes are increasing rapidly. One of the causes of the disease is dry eye (dry eye). Generally, dry eye refers to a state in which the cornea or conjunctiva on the surface of the eyeball is damaged due to a decrease in the amount of secretion of tears or a qualitative change in tears. On the surface of the normal eye, tears blink to a thin film that protects the eye from drying, dust, and bacteria. However, when dry eye occurs, the surface of the eye cannot be sufficiently protected, and damage to the cornea and conjunctiva occurs. Because dry eye not only dries the eye but also damages the surface of the eye, early measures are needed before developing various eye diseases.
[0003]
Tear fluid is composed of three layers: an oil layer, an aqueous layer, and a mucin layer. A common treatment for dry eye that has been used so far is to apply artificial tears to replenish the aqueous layer Eye drops such as sodium chondroitin sulfate and sodium hyaluronate, which have a water retention effect, have been used for the purpose of replenishing the mucin layer. However, none of these promote natural tear secretion.
[0004]
Conventionally, phenylephrine has been widely used in eye drops for the purpose of removing hyperemia based on vasoconstriction. Further, flavin adenine dinucleotide (which can be abbreviated as FAD) is already known to be effective for treating dry eye (Patent Document 1).
[Patent Document 1]
JP-A-11-263729
[Problems to be solved by the invention]
An object of the present invention is to provide an ophthalmic solution composition that is more effective and safely improves various symptoms associated with dry eye by actively promoting the secretion of tears.
[0006]
[Means for Solving the Problems]
The present inventors have conducted intensive studies to solve the above problems, and as a result, have found that by combining phenylephrine and flavin adenine dinucleotide, synergistically enhance the lacrimal secretion promoting action, and completed the present invention. .
[0007]
That is, the present invention is characterized in that (1) ophthalmic composition characterized by containing a combination of phenylephrine and vitamin B 2 compounds, (2) Vitamin B 2 compounds are flavin adenine dinucleotide (1) (3) The ophthalmic composition according to (1) or (2), which is for preventing or improving dry eye.
[0008]
BEST MODE FOR CARRYING OUT THE INVENTION
INDUSTRIAL APPLICABILITY The present invention is effective for preventing or improving dry eye, eye fatigue, blurring, itching, conjunctival congestion, blepharitis, ophthalmitis, and discomfort when wearing a contact lens due to decreased tear secretion.
[0009]
Vitamin B 2 compounds for use in the present invention, flavin adenine dinucleotide and its salts, riboflavin phosphate and its salts, acetic riboflavin, and the like riboflavin butyrate. Of these, preferred is flavin adenine dinucleotide, and most preferred is flavin adenine dinucleotide disodium. When flavin adenine dinucleotide is used, it can be blended at a ratio of 0.005% by mass to 5.0% by mass of the whole liquid preparation, preferably 0.01% by mass to 1.0% by mass, and Preferably it is 0.02% by mass to 0.05% by mass.
[0010]
The phenylephrine used in the present invention can be added at a ratio of 0.0001% by mass to 10.0% by mass, preferably 0.005% by mass to 1.0% by mass, and more preferably 0.01% by mass. % To 0.1% by mass. The compounding form of phenylephrine is not limited, but phenylephrine hydrochloride is particularly preferred.
[0011]
In the present invention, other medicinal ingredients can be blended as necessary within a qualitative and quantitative range that does not impair the effects of the present invention.
[0012]
【The invention's effect】
According to the present invention, an ophthalmic composition for preventing or improving dry eye, eye fatigue, blurring, itching, conjunctival hyperemia, blepharitis, ophthalmitis, and discomfort when wearing contact lenses according to the present invention. Is now available.
[0013]
【Example】
Hereinafter, the present invention will be described specifically with reference to Test Examples and Examples.
Test Example 1, Comparative Examples 1-2, Control Example 1
Male Japanese white rabbits weighing about 2.5 kg were grouped into 5 rabbits. Rabbit eyes were instilled with 50 μl of 0.4% by mass oxybuprocaine hydrochloride twice at 3 minute intervals, and after 3 minutes, 50 μl of the test ophthalmic sample was instilled into one eye and saline was instilled into the other eye. Each of the test eye drop samples was dissolved in physiological saline and adjusted to the following concentrations. Five minutes, ten minutes, fifteen minutes, and thirty minutes after instillation, tears were collected by inserting Schirmer test paper (strip-shaped filter paper of 5 mm x 35 mm) into the lower eyelid for one minute. The amount of tear secretion was measured by measuring the wet length of Schirmer test paper using a caliper, and the amount of tear was measured from the total value of the lengths.
Comparative Example 1: Solution containing 0.1% by mass phenylephrine hydrochloride Comparative Example 2: Solution containing 0.05% by mass FAD solution Test Example 1: 0.1% by mass phenylephrine hydrochloride solution and 0.05% by mass FAD solution Is shown in Table 1.
[0014]
[Table 1]
As shown in Table 1, the 0.1% by mass phenylephrine hydrochloride solution of Comparative Example 1 and the 0.05% by mass FAD solution of Comparative Example 2 showed no change in the amount of tear secretion as compared with physiological saline. However, in the 0.1% by mass phenylephrine hydrochloride solution and the 0.05% by mass FAD solution of Test Example 1, a significant increase in the amount of tear secretion was observed. From the above results, it was revealed that the ophthalmic composition containing phenylephrine and FAD had an enhanced lacrimal secretion promoting effect as compared to FAD alone or phenylephrine alone.
Example 1
Dissolve 0.1 g of phenylephrine hydrochloride and 0.05 g of disodium flavin adenine dinucleotide in 90 ml of sterilized purified water, adjust the pH to 7.4 with borax, and add sterile purified water to make the total volume 100 ml. An agent was prepared.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003009202A JP2004217596A (en) | 2003-01-17 | 2003-01-17 | Eye drop agent composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003009202A JP2004217596A (en) | 2003-01-17 | 2003-01-17 | Eye drop agent composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004217596A true JP2004217596A (en) | 2004-08-05 |
Family
ID=32898765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003009202A Pending JP2004217596A (en) | 2003-01-17 | 2003-01-17 | Eye drop agent composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2004217596A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009534372A (en) * | 2006-04-28 | 2009-09-24 | ザ プロクター アンド ギャンブル カンパニー | Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory diseases |
| WO2019230834A1 (en) * | 2018-05-31 | 2019-12-05 | ライオン株式会社 | Tear film stabilizer, meibum secretion promoter, and ophthalmic composition |
| JP2019210282A (en) * | 2018-05-31 | 2019-12-12 | ライオン株式会社 | Tear film stabilizer and meibum secretion promoter |
| JP2020105086A (en) * | 2018-12-26 | 2020-07-09 | ライオン株式会社 | Ophthalmic composition |
| US10772848B2 (en) | 2006-04-21 | 2020-09-15 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| CN112839641A (en) * | 2018-12-26 | 2021-05-25 | 狮王株式会社 | Ophthalmic composition |
| US11141415B2 (en) | 2006-04-21 | 2021-10-12 | The Procter & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
-
2003
- 2003-01-17 JP JP2003009202A patent/JP2004217596A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11491151B2 (en) | 2006-04-21 | 2022-11-08 | The Procter & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
| US10772848B2 (en) | 2006-04-21 | 2020-09-15 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| US11077074B2 (en) | 2006-04-21 | 2021-08-03 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| US11083697B2 (en) | 2006-04-21 | 2021-08-10 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| US11141415B2 (en) | 2006-04-21 | 2021-10-12 | The Procter & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
| JP2009534372A (en) * | 2006-04-28 | 2009-09-24 | ザ プロクター アンド ギャンブル カンパニー | Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory diseases |
| WO2019230834A1 (en) * | 2018-05-31 | 2019-12-05 | ライオン株式会社 | Tear film stabilizer, meibum secretion promoter, and ophthalmic composition |
| JP2019210282A (en) * | 2018-05-31 | 2019-12-12 | ライオン株式会社 | Tear film stabilizer and meibum secretion promoter |
| CN112203687A (en) * | 2018-05-31 | 2021-01-08 | 狮王株式会社 | Tear film stabilizer, meibum secretion promoter, and ophthalmic composition |
| JP7404658B2 (en) | 2018-05-31 | 2023-12-26 | ライオン株式会社 | Tear film stabilizer and meibum secretion promoter |
| JP2020105086A (en) * | 2018-12-26 | 2020-07-09 | ライオン株式会社 | Ophthalmic composition |
| JP7192489B2 (en) | 2018-12-26 | 2022-12-20 | ライオン株式会社 | Ophthalmic composition |
| CN112839641A (en) * | 2018-12-26 | 2021-05-25 | 狮王株式会社 | Ophthalmic composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5616620B2 (en) | Nonionic silicone hydrogel contact lens ophthalmic composition | |
| EP1165731A1 (en) | A viscosity enhanced ophthalmic solution, having a detergent action on contact lenses | |
| RU2700927C2 (en) | Ophthalmic composition containing cyclosporine and trehalose | |
| JP2018104474A (en) | Ophthalmic composition for silicone hydrogel contact lens | |
| JP2018135376A (en) | Ophthalmic composition for silicone hydrogel contact lenses | |
| JP4987078B2 (en) | Ophthalmic composition | |
| JP2004217596A (en) | Eye drop agent composition | |
| JP5725786B2 (en) | Nonionic silicone hydrogel contact lens ophthalmic composition | |
| JP6449774B2 (en) | Ophthalmic composition for zwitterionic soft contact lenses | |
| JP2006507275A (en) | 3-layer tear preparation | |
| JP4736540B2 (en) | Ophthalmic thickener | |
| JP2011111441A (en) | Ophthalmic composition for nonionic silicone hydrogel contact lens | |
| ITMI980555A1 (en) | WETTING AND LUBRICANT SOLUTION FOR OPHTHALMIC USE | |
| JP5650864B2 (en) | Nonionic silicone hydrogel contact lens ophthalmic composition | |
| TWI671082B (en) | Ophthalmic composition for anionic soft contact lenses | |
| JP2007077053A (en) | Ophthalmic liquid preparation composition | |
| JP2006052160A (en) | Ophthalmic composition for treating dry eye | |
| JP4778515B2 (en) | Treatment for corneal diseases | |
| JP5506357B2 (en) | Ophthalmic composition for silicone hydrogel contact lens | |
| WO2009157596A1 (en) | Ophthalmic composition for preventing and treating ocular diseases | |
| TW202027733A (en) | Lutein-containing ophthalmic composition | |
| JPH08133968A (en) | Ophthalmic preparation for repairing corneal damage | |
| KR20080077585A (en) | Ophthalmic composition for preventing and treating ocular diseases | |
| JP2015028090A (en) | Ophthalmic composition for nonionic silicone hydrogel contact lens | |
| TWI626060B (en) | Ophthalmic composition for zwitterionic soft contact lens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051223 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090630 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091027 |